Last year, Ascendis Pharma A/S generated 683.57M USD for its biggest-performing segment, Commercial sale of products. The North America made the largest contribution, accounting for 546.39M USD last year. For the latest quarter, Ascendis Pharma A/S reported the revenue of 314.91M USD for the period ending 2026-06-30, which came from the top-performing segment, Commercial sale of products. North America contributed the highest revenue, at 265.47M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Commercial sale of products

Rendering of services

Milestones

License

Sale of clinical supply

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Commercial sale of products

683.57M(94.92%)

225.73M(62.07%)

178.66M(66.99%)

35.66M(69.68%)

943.00K(12.12%)

--(--)

Rendering of services

18.01M(2.50%)

11.79M(3.24%)

21.66M(8.12%)

4.43M(8.66%)

751.00K(9.66%)

2.14M(30.78%)

9.92M(74.16%)

Milestones

12.92M(1.79%)

--(--)

License

5.63M(0.78%)

122.34M(33.64%)

66.08M(24.77%)

2.55M(4.98%)

2.37M(30.41%)

2.61M(37.49%)

2.65M(19.83%)

Sale of clinical supply

--(--)

3.78M(1.04%)

319.00K(0.12%)

8.53M(16.68%)

3.72M(47.81%)

2.21M(31.73%)

804.00K(6.01%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

North America

Europe

Rest of world

Denmark

Asia

China

FY2025

FY2024

FY2022

FY2021

FY2020

North America

546.39M(75.87%)

233.22M(64.13%)

44.16M(86.29%)

6.86M(88.15%)

2.68M(38.53%)

Europe

108.05M(15.00%)

27.94M(7.68%)

552.00K(1.08%)

--(--)

Rest of world

52.80M(7.33%)

7.08M(1.95%)

6.47M(12.64%)

--(--)

Denmark

12.90M(1.79%)

95.40M(26.23%)

--(--)

Asia

--(--)

922.00K(11.85%)

--(--)

China

--(--)

4.27M(61.47%)